54 reports of this reaction
2.4% of all NELARABINE reports
#6 most reported adverse reaction
MUSCULAR WEAKNESS is the #6 most commonly reported adverse reaction for NELARABINE, manufactured by Novartis Pharmaceuticals Corporation. There are 54 FDA adverse event reports linking NELARABINE to MUSCULAR WEAKNESS. This represents approximately 2.4% of all 2,208 adverse event reports for this drug.
Patients taking NELARABINE who experience muscular weakness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MUSCULAR WEAKNESS is a less commonly reported adverse event for NELARABINE, but still significant enough to appear in the safety profile.
In addition to muscular weakness, the following adverse reactions have been reported for NELARABINE:
The following drugs have also been linked to muscular weakness in FDA adverse event reports:
MUSCULAR WEAKNESS has been reported as an adverse event in 54 FDA reports for NELARABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MUSCULAR WEAKNESS accounts for approximately 2.4% of all adverse event reports for NELARABINE, making it a notable side effect.
If you experience muscular weakness while taking NELARABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.